1264 related articles for article (PubMed ID: 28486906)
41. European Commission-supported development of targeted nanomedicines: did MediTrans make a difference?
Storm G; Aime S
Ther Deliv; 2011 Jul; 2(7):861-4. PubMed ID: 22833900
[TBL] [Abstract][Full Text] [Related]
42. Nanoparticles: pharmacological and toxicological significance.
Medina C; Santos-Martinez MJ; Radomski A; Corrigan OI; Radomski MW
Br J Pharmacol; 2007 Mar; 150(5):552-8. PubMed ID: 17245366
[TBL] [Abstract][Full Text] [Related]
43. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
44. Nanomedicines: Redefining traditional medicine.
Lu W; Yao J; Zhu X; Qi Y
Biomed Pharmacother; 2021 Feb; 134():111103. PubMed ID: 33338747
[TBL] [Abstract][Full Text] [Related]
45. The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine.
Cai R; Chen C
Adv Mater; 2019 Nov; 31(45):e1805740. PubMed ID: 30589115
[TBL] [Abstract][Full Text] [Related]
46. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
Bhattacharjee S; Brayden DJ
Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
[TBL] [Abstract][Full Text] [Related]
47. Nanomedicine at the crossroads - A quick guide for IVIVC.
Mast MP; Modh H; Champanhac C; Wang JW; Storm G; Krämer J; Mailänder V; Pastorin G; Wacker MG
Adv Drug Deliv Rev; 2021 Dec; 179():113829. PubMed ID: 34174332
[TBL] [Abstract][Full Text] [Related]
48. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
49. Toxicological assessment of nanoparticle interactions with the pulmonary system.
Osman NM; Sexton DW; Saleem IY
Nanotoxicology; 2020 Feb; 14(1):21-58. PubMed ID: 31502904
[TBL] [Abstract][Full Text] [Related]
50. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
51. Regulatory aspects on nanomedicines.
Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
[TBL] [Abstract][Full Text] [Related]
52. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
Mühlebach S; Borchard G; Yildiz S
Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
[TBL] [Abstract][Full Text] [Related]
53. Trends in Nanomedicines for Cancer Treatment.
do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
[TBL] [Abstract][Full Text] [Related]
54. Purification processes of polymeric nanoparticles: How to improve their clinical translation?
Tehrani SF; Bharadwaj P; Leblond Chain J; Roullin VG
J Control Release; 2023 Aug; 360():591-612. PubMed ID: 37422123
[TBL] [Abstract][Full Text] [Related]
55. Nanomedicines: From Bench to Bedside and Beyond.
Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
[TBL] [Abstract][Full Text] [Related]
56. Nano based drug delivery systems: recent developments and future prospects.
Patra JK; Das G; Fraceto LF; Campos EVR; Rodriguez-Torres MDP; Acosta-Torres LS; Diaz-Torres LA; Grillo R; Swamy MK; Sharma S; Habtemariam S; Shin HS
J Nanobiotechnology; 2018 Sep; 16(1):71. PubMed ID: 30231877
[TBL] [Abstract][Full Text] [Related]
57. Nanomedicines for Renal Management: From Imaging to Treatment.
Jiang D; Rosenkrans ZT; Ni D; Lin J; Huang P; Cai W
Acc Chem Res; 2020 Sep; 53(9):1869-1880. PubMed ID: 32786331
[TBL] [Abstract][Full Text] [Related]
58. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
Rubinstein I; Weinberg GL
Maturitas; 2012 Sep; 73(1):68-73. PubMed ID: 22264497
[TBL] [Abstract][Full Text] [Related]
59. Nanotechnology: Revolutionizing the Science of Drug Delivery.
Mishra M; Kumar P; Rajawat JS; Malik R; Sharma G; Modgil A
Curr Pharm Des; 2018; 24(43):5086-5107. PubMed ID: 30727873
[TBL] [Abstract][Full Text] [Related]
60. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
